Medivir
2.89
SEK
+0.35 %
MVIR
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
www.medivir.com/investors
Medivir is a pharmaceutical company. The company develops drugs and treatments with a focus on cancers and other serious diseases. The company invests in indication areas where available treatment methods are limited or completely lacking research. Collaborations with other partners are part of the business model, and drug development, as well as commercialization, are conducted either in-house or in partnership with other pharmaceutical companies. The head office is located in Huddinge.
Revenue
7.6M
EBIT %
-1,202.63 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
MVIR
Daily low / high price
2.7 / 2.89
SEK
Market cap
331.25M SEK
Turnover
319.81K SEK
Volume
114K
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Linc AB | 11.2 % | 11.4 % |
Nordea Funds AB | 8.7 % | 8.9 % |
Avanza Pension | 7.2 % | 7.4 % |
Hallberg Management AB | 6.6 % | 6.7 % |
HealthInvest Partners AB | 3.7 % | 3.8 % |
Nordnet Pensionsförsäkring AB | 2.8 % | 2.9 % |
NGL Förvaltning AB | 2.4 % | 2.4 % |
Johan Claesson | 2.2 % | 2.3 % |
CA Fastigheter AB | 2.1 % | 2.1 % |
Privatperson | 2.1 % | 2.2 % |
ShowingAll content types
MEDIVIR AB – DELÅRSRAPPORT JANUARI – SEPTEMBER 2024
MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools